Results

RDF/XMLNTriplesTurtleShow queryShare ▶
SubjectPredicateObject
http://purl.uniprot.org/citations/19727662http://www.w3.org/1999/02/22-rdf-syntax-ns#typehttp://purl.uniprot.org/core/Journal_Citation
http://purl.uniprot.org/citations/19727662http://www.w3.org/2000/01/rdf-schema#comment"

Aims/hypothesis

Extracellular pre-B cell colony-enhancing factor/nicotinamide phosphoribosyltransferase/visfatin (ePBEF/NAMPT/visfatin) is an adipocytokine, whose circulating levels are enhanced in metabolic disorders, such as diabetes mellitus and obesity. Here, we explored the ability of ePBEF/NAMPT/visfatin to promote vascular inflammation, as a condition closely related to atherothrombotic diseases. We specifically studied the ability of PBEF/NAMPT/visfatin to directly activate pathways leading to inducible nitric oxide synthase (iNOS) induction in cultured human aortic smooth muscle cells, as well as the mechanisms involved.

Methods

iNOS levels and extracellular signal-regulated kinase (ERK) 1/2 activity were determined by western blotting. Nuclear factor (NF)-kappaB activity was assessed by electrophoretic mobility shift assay.

Results

ePBEF/NAMPT/visfatin (10-250 ng/ml) induced iNOS in a concentration-dependent manner. At a submaximal concentration (100 ng/ml), ePBEF/NAMPT/visfatin time-dependently enhanced iNOS levels up to 18 h after stimulation. Over this time period, ePBEF/NAMPT/visfatin elicited a sustained activation of NF-kappaB and triggered a biphasic ERK 1/2 activation. By using the respective ERK 1/2 and NF-kappaB inhibitors, PD98059 and pyrrolidine dithiocarbamate, we established that iNOS induction by ePBEF/NAMPT/visfatin required the consecutive upstream activation of ERK 1/2 and NF-kappaB. The pro-inflammatory action of ePBEF/NAMPT/visfatin was not prevented by insulin receptor blockade. However, exogenous nicotinamide mononucleotide, the product of NAMPT activity, mimicked NF-kappaB activation and iNOS induction by ePBEF/NAMPT/visfatin, while the NAMPT inhibitor APO866 prevented the effects of ePBEF/NAMPT/visfatin on iNOS and NF-kappaB.

Conclusions/interpretation

Through its intrinsic NAMPT activity, ePBEF/NAMPT/visfatin appears to be a direct contributor to vascular inflammation, a key feature of atherothrombotic diseases linked to metabolic disorders."xsd:string
http://purl.uniprot.org/citations/19727662http://purl.org/dc/terms/identifier"doi:10.1007/s00125-009-1509-2"xsd:string
http://purl.uniprot.org/citations/19727662http://purl.uniprot.org/core/author"Sanchez-Ferrer C.F."xsd:string
http://purl.uniprot.org/citations/19727662http://purl.uniprot.org/core/author"Nevado J."xsd:string
http://purl.uniprot.org/citations/19727662http://purl.uniprot.org/core/author"Romacho T."xsd:string
http://purl.uniprot.org/citations/19727662http://purl.uniprot.org/core/author"Carraro R."xsd:string
http://purl.uniprot.org/citations/19727662http://purl.uniprot.org/core/author"Cercas E."xsd:string
http://purl.uniprot.org/citations/19727662http://purl.uniprot.org/core/author"Peiro C."xsd:string
http://purl.uniprot.org/citations/19727662http://purl.uniprot.org/core/author"Rodriguez-Manas L."xsd:string
http://purl.uniprot.org/citations/19727662http://purl.uniprot.org/core/author"Azcutia V."xsd:string
http://purl.uniprot.org/citations/19727662http://purl.uniprot.org/core/author"Matesanz N."xsd:string
http://purl.uniprot.org/citations/19727662http://purl.uniprot.org/core/author"Vazquez-Bella M."xsd:string
http://purl.uniprot.org/citations/19727662http://purl.uniprot.org/core/date"2009"xsd:gYear
http://purl.uniprot.org/citations/19727662http://purl.uniprot.org/core/name"Diabetologia"xsd:string
http://purl.uniprot.org/citations/19727662http://purl.uniprot.org/core/pages"2455-2463"xsd:string
http://purl.uniprot.org/citations/19727662http://purl.uniprot.org/core/title"Extracellular PBEF/NAMPT/visfatin activates pro-inflammatory signalling in human vascular smooth muscle cells through nicotinamide phosphoribosyltransferase activity."xsd:string
http://purl.uniprot.org/citations/19727662http://purl.uniprot.org/core/volume"52"xsd:string
http://purl.uniprot.org/citations/19727662http://www.w3.org/2004/02/skos/core#exactMatchhttp://purl.uniprot.org/pubmed/19727662
http://purl.uniprot.org/citations/19727662http://xmlns.com/foaf/0.1/primaryTopicOfhttps://pubmed.ncbi.nlm.nih.gov/19727662
http://purl.uniprot.org/uniprot/P01308#attribution-8AA0BD3DA9363A90D453AECA4953E061http://purl.uniprot.org/core/sourcehttp://purl.uniprot.org/citations/19727662
http://purl.uniprot.org/uniprot/P43490#attribution-8AA0BD3DA9363A90D453AECA4953E061http://purl.uniprot.org/core/sourcehttp://purl.uniprot.org/citations/19727662
http://purl.uniprot.org/uniprot/#_Q3V449-mappedCitation-19727662http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/19727662
http://purl.uniprot.org/uniprot/#_Q3V455-mappedCitation-19727662http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/19727662
http://purl.uniprot.org/uniprot/#_Q9EPA7-mappedCitation-19727662http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/19727662
▶